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Abstract
Ketamine has been extensively used in the medical field for more than 50 years, 
but its exact mechanism of action remains unknown. It's used to induce dissociative 
anesthesia (a state of profound analgesia, amnesia with light sleep, immobility, and 
a sense of disassociation from one's own body and surroundings). Clinical studies 
on ketamine as a dissociative anesthetic, a model for psychosis, and as a rapidly 
acting antidepressant have sparked great interest in understanding its effects at the 
molecular and cellular level. It exerts uncompetitive inhibitory effects on NMDARs 
(N-Methyl-D-asperate) and may preferentially affect the function of NMDARs in 
interneurons. The hypnotic effects of this drug are attributed to its blocking action 
on NMDA and HCN1 receptors; however, both positive and negative modulation 
of choline, amine, and opioid systems appears to occur. It is likely that ketamine's 
effect on chronic pain and depression far outlasts its actual levels. This could be due 
to the hyperglutamatergic state induced by ketamine causing a secondary increase 
in structural synaptic connectivity. The authors of this review have attempted to 
highlight the action of ketamine not only on NMDA receptors but also on a variety 
of biochemical processes and functions found in intercellular environments, which 
may explain its diverse role in many diseases.
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1. Introduction
Ketamine is an anesthetic drug that has been used for around more than 50 years in 
the medical field. In contrast to more traditional volatile-based anesthesia, it produces 
a broader range of anesthetic effects, resulting in a qualitatively different type of anes-
thesia [1]. This state is known as “dissociative anesthesia”. These include: (a) hypnosis 
with psychotomimetic properties at low doses, accompanied by increased sedation 
and unconsciousness at higher doses; (b) analgesic properties (or antinociception); 
(c) sympathetic stimulation; and (d) maintenance of intrapulmonary pressure and 
respiratory regulation. Research has found that ketamine inhibits the N-methyl-D-
aspartate (NMDA) receptor in a dose-dependent manner and that this blocking of 
excitatory synaptic activity [2]. It is responsible for the loss of responsiveness associ-
ated with clinical ketamine anesthesia. However, later scientific research has revealed 
that it has a wide array of molecular effects that have a clinically beneficial effect on 
many illnesses, including acute and chronic pain, and recently as an antidepressant 
with a rapid onset [3]. It is intriguing to note that many of these therapeutically 
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beneficial effects appear long after the drugs are almost fully eliminated from the 
body. The link between drug binding and therapeutic outcomes is more intricate than 
previously understood.
Researchers and Clinicians are increasingly keen to understand the exact 
mechanism of action by which ketamine and other N-methyl-D-aspartate recep-
tors (NMDAR) antagonists affect the brain [4]. Pioneering investigations by 
Krystal and colleagues in the early 1990s established that a 40-minute subanes-
thetic infusion of ketamine (0.5 mg/kg) produced temporary psychotic symptoms 
in otherwise healthy subjects. As a result of ketamine infusions, sensory illusions, 
persecutory ideas, and altered cognition, including difficulties with attention, 
word-finding, and acute learning difficulties were observed. A few hours after 
cessation of the infusion, these symptoms disappeared [5]. Researchers discov-
ered that in patients with major depression, the same ketamine infusion produces 
a slower but still rapid antidepressant effect. In some patients, this effect began 
within a few hours of ketamine infusion and lasted for a week or more [6]. 
Additionally, it has shown antidepressant effects, including rapid improve-
ments in suicidal thoughts in patients with treatment-resistant depression [7]. 
Ketamine does not bind closed NMDAR channels; instead, it requires them to 
open before it can cause antagonistic effects. In a similar manner to phencyclidine 
and MK-801, ketamine also causes an open channel block that involves binding 
to an electrically deep part within the channel, which stops ion flow, persisting 
within the channel until the channel closes. The latter attribute is responsible for 
an extended block relieved by channel opening [8]. In the membrane depolariza-
tion theory, the dissociation of drugs is accelerated, but an electrostatic model of 
voltage dependence does not fully explain the mechanism by which it decreases 
block. Ketamine is less effective than phencyclidine and MK-801 due to its quicker 
dissociation from the open channel [9]. Despite the fact that it is not selective 
for NMDARs, and recent research has called into question the significance of 
NMDAR antagonism as an antidepressant, the effects of ketamine on NMDARs 
appear to contribute significantly to its analgesic, anesthetic, and psychotomi-
metic, if not antidepressant, properties [10]. The research is yielding a plethora of 
innovative hypotheses about mood and psychotic illnesses, including the possible 
function of NMDARs in these diseases and the application of novel therapeutic 
approaches. In this review, we will provide a wide overview of the available data 
on ketamine’s effects and possible repercussions [11].
2. Ketamine and its molecular effects
2.1 Immediate effects
It is now known that ketamine directly influences a wide range of cellular 
processes in clinical doses. In this case, as shown in Figure 1, the effects include 
blocking NMDA channels, hyperpolarization-induced cationic currents (also 
known as hyperpolarization-activated cyclic nucleotide channels (HCN1)), 
nicotinic acetylcholine channels, delta, opioid receptor agonists and potentiators 
[12], the nitric oxide (NO)–cyclic guanosine-mono-phosphate (cGMP) system, 
non-NMDA glutamate receptors (α-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA)), and metabotropic glutamate receptors (mGluR), 
decreased activity of cholinergic neurons, stimulation of aminergic neurons 
(dopamine and noradrenaline), L-type Ca2+ channels, and neurosteroids. Each of 
these systems is a component of the integrated nervous system, and they interact 
at all levels [13, 14].
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2.2 Disruption of NMDA channel functions by ketamine
There is a great deal of complexity in the way in which several groups of compounds 
affect NMDA receptor function at the level of chemical binding, and this is explored in 
great detail in this review. Many compounds have been shown to influence the action 
of NMDA. Generally, they fall into the following categories: (a) open channel blockers 
(ketamine is one of the least potents), (b) competitive antagonists, and (c) allosteric 
modulators, (d) non-competitive antagonists [12, 15]. In all of these compounds, the 
relative potency of their action on the various NMDA receptor subtypes is different 
(commonly termed GluN1, GluN2A, GluN2B, GluN2C, and GluN2D – but also called 
NR1, NR2A-D) [16]. The distributions of these subtypes in the brain are markedly 
heterogeneous, which may explain why different NMDA blocking compounds produce 
different clinical effects. GluN2A is reported to be present throughout the brain, while 
GluN2B is present mainly in limbic systems, thalamus, and spinal cord. The thalamus 
and cerebellum contain GluN2C, whereas the brain stem, diencephalon, and spinal 
cord contain GluN2D. The off-rate of the compound is another important reason for the 
variation in effect. The phenomenon is known as “trapping block” [17]. High-trapping 
antagonists with a slow off-rate include compounds such as ketamine (86% trapping) 
and MK-801 (almost 100% trapping) [18]. After glutamate has dissociated from its 
binding site on the NMDA receptor, ketamine remains trapped in the closed ion chan-
nel, disrupting both physiological and pathological functions. Conversely, low-trapping 
(fast off-rate) antagonists escape the channel before it closes, preserving NMDA 
function at some level, and having fewer side effects. As an example, the compound 
memantine (50–70%) has minimal psychotomimetic or sedative effects. This is a 
slow-off-rate, low-affinity open-channel blocker. Thus, it blocks NMDA channels only 
when they are pathologically open, but not when they are temporarily open as in most 
physiological states [19]. In many ways, this mechanism is similar to persistent sodium 
channel blockers used in antiepileptic drugs. The end result is an NMDA blocker 
without any apparent anesthetic effects.
Figure 1. 
There are immediate effects and actions on the left, and delayed and prolonged ones on the right. [NMDA: 
N-methyl-d aspartate, HCN1: Hyperpolarization-activated cyclic nucleotide channels, ACh: Acetylcholine, 
nACh: Nicotinic acetylcholine receptors, AMPA: α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, 
mGluR: Metabotropic glutamate receptors, ERK1/2: Extracellular signal-regulated kinases, NOX: NADPH 
oxidase, BDNF: Brain-derived neurotrophic factor, mTOR: Mammalian target of rapamycin, Rgs4: Regulator 
of G protein signaling 4, L-type Ca2+: L-type calcium channels, GFAP: Glial fibrillary acidic protein].
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2.3 Ketamine possesses delayed effects
The functions of a cell go far beyond ion channels. Almost every immediate 
effect of ketamine disrupts subsequent and more long-lasting cellular processes, 
including gene expression and protein metabolism. It is not surprising since 
NMDA is largely responsible for calcium entry into cells, and calcium ions 
play a significant role in protein and mitochondrial metabolism. In subjects 
with mechanical injuries, it suppresses immediate early gene expression (fosB, 
c-jun, junD, zif/268, c-fos, junB,) [20]. A rat and mouse model of hyperalgesia 
have shown altered NMDA receptor1 phosphorylation and NMDA receptor1 
mRNA expression [21], which has reduced the expression of the glial fibrillary 
acidic protein (GFAP) and also reduction in astrocytic and microglial activa-
tion [22, 23], an effect that is associated with reduced neuropathic pain. These 
chronic pain models represent complex patterns of nociception, but they may 
also encompass acute pain. A study found that ketamine can affect the number 
and function of synaptic connections in rat hippocampal regions by increasing 
brain-derived neurotrophic factor (BDNF) and mammalian target of rapamycin 
(mTOR) [24, 25] protein levels.
3. Psychotomimetic effects of ketamine
Aside from encouraging illegal usage, the psychotomimetic effects of ketamine 
can lead to distressing psychic disturbances, particularly in children, with the risk 
of experiencing nightmares, hallucinations, and delirium. Recent studies reveal that 
ketamine disrupts synaptic homeostasis - either by altering the release or uptake 
of neurotransmitters or by modifying neuromodulator activity. In addition, one 
intriguing possibility is that ketamine might inhibit NADPH oxidase (NOX2) from 
controlling glutamate release. There has been an association between psychosis 
and an excess of glutamate activity [26]. Alternatively, or perhaps simultaneously, 
ketamine may disrupt RGS4 (Regulator of G protein signaling 4). This particular 
protein regulates the G protein-coupled receptors such as opiate and muscarinic 
receptors [27]. Historically, ketamine’s effects in increasing dopamine production 
[28] along with a possible decrease in acetylcholine activity [14] will be responsible 
for aggravating delirium.
The oral formulation of ketamine offers an effective analgesic for patients with 
chronic pain. In a study of 21 patients with chronic neuropathic pain in the central 
and peripheral nerves, the starting dose of oral ketamine was 100 mg/day, which 
was gradually increased by 40 mg/day every 2 days until the desired effect was 
achieved. Nine of the 21 patients stopped using ketamine because of unpleasant side 
effects, including psychotomimetic effects such as dissociative experiences, somatic 
sensations, sleep, and taste abnormalities [26]. During a double-blind, random-
ized placebo-controlled study, 73 traumatized participants with severe acute 
pain (expressed on a visual analog pain scale) were administered either ketamine 
0.2 mg/kg or placebo (isotonic saltwater) along with morphine 0.1 mg/kg followed 
by 3 mg every 3 minutes [29]. There was a significant reduction in consumption of 
morphine with ketamine (0.20 mg/kg versus 0.15 mg/kg), even though no differ-
ences were noted in the pain scores. It showed a greater degree of adverse effects, 
including increased incidences of neuropsychiatric symptoms. Patients in both 
groups found their treatments satisfactory and no adverse reactions were requiring 
additional treatment [30]. Due to the short study period (30 minutes), it is possible 
that adverse reactions were not identified as a result of this, although a power study 
was not designed to explore this.
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Again, in a randomized, double-blind, placebo-controlled study involving 120 
people who underwent elective laparotomy, the effects of administering ketamine 
0.1 mg/kg/hour along with tramadol 0.2 mg/kg/hour were evaluated. The ketamine 
group consumed 54% less morphine compared with the placebo group, resulting 
in superior analgesia. No differences were found in nausea and use of antiemetic 
drugs, mental performance, sleep difficulties, or non-disturbing hallucinations. 
However, there were three patients, receiving ketamine who opted out of the study 
because they experienced disconcerting hallucinations [31].
A linear relationship between plasma ketamine concentrations of 50–200 ng/ml 
and psychotomimetic effects was observed in a placebo-controlled experiment on 
10 healthy young men. The psychedelic effects were similar to those reported in an 
earlier study of dimethyltryptamine, an illegal LSD-25 type of drug. Additionally, 
the effects were proportional to plasma concentrations rather than simply one of 
emergence. In clinical studies, plasma levels of 100–200 ng/ml resulted in useful 
analgesia. Observations of lateral nystagmus were consistent across subjects at 
200 ng/ml plasma concentrations. Large doses of ketamine rapidly cause patients to 
become unconscious, and therefore the effects that were observed in this study are 
usually only evident afterward [32, 33].
Ketamine is a racemic mixture consisting of two enantiomers, R- and 
S-ketamine. Both of the enantiomers displays similar pharmacological effect but 
there is a question regarding the psychotomimetic effects of these enantiomers. 
Earlier research findings reported S-ketamine to be less prone to psychotomimetic 
side effects as compared to R-ketamine. While recent studies reported R-Ketamine 
to cause fewer psychotomimetic side effects. In a recent study with 11 partici-
pants, the pharmacological and psychotomimetic effect of R- and S-enantiomeric 
ketamine has been tested. The participants received 0.5 mg R-ketamine and then 
0.15 mg S-ketamine separately for 1 week. [34]. Using a nerve stimulator placed 
on the right central incisor tooth, these subjects were exposed to painful stimula-
tion before and after the administration of each drug. Both drugs were equally 
effective in suppressing pain. The subjects reported that S-ketamine produced 
less pleasant psychotomimetic effects than R-ketamine. Of the 11 subjects, seven 
preferred R-ketamine to S-ketamine [35]. Based on these results, it is considered 
that ketamine may have a significant neuropsychiatric effect predominantly due 
to its S-enantiomer, making R-ketamine an ideal alternative. In contrast to earlier 
research suggesting that the most serious neuropsychiatric side effects are caused 
by R-ketamine, this study finds no evidence of this.
4. Hypnosis
Ketamine loses its vulnerability when the concentration is about 20 times higher 
(about 2000 ng/ml) than the concentration required inducing psychotropic effects. 
Because it has an elimination half-life of approximately 3 hours, there is a prolonged 
period during which drug levels are near the concentrations required to produce 
psychomimetic effects. [36]. It should also be noted that the duration of hypnosis 
strictly corresponds to changes in drug concentration in the blood (and the site of 
action), indicating that the slow side effects in hypnosis/anesthesia do not have a 
significant causal effect. Ketamine is anomalous among commonly used anesthetics 
in that it has a strange combination of tranquilizers (such as NMDA antagonism) 
and stimulants (increasing amines, excess glutamate, and increasing AMPA recep-
tor administration), as well as molecular effects. As a result, achieving complete 
anesthesia is difficult. Ketamine is typically used in conjunction with 2-adrenergic 
agonists to achieve surgical anesthesia in many animal species and veterinary 
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anesthesia. It causes central nervous system depression because the NMDA receptors 
on the dendrites of inhibitory neurons are less sensitive to the effects of ketamine 
than the receptors on excitatory neurons [37].
In hypnosis, other molecular effects may play significant roles in addition to 
NMDA blockade. Numerous sources provide evidence on this point. As a first point, 
the hypnotic effect is unrelated to NMDA blockade effectiveness. Numerous NMDA 
blocker compounds, including dizocilpine maleate (MK801) and dextrorphan, 
have weak hypnotic effects. This difference may be explained by ketamine having a 
considerably stronger effect on GluN2C receptors which would theoretically cause 
more thalamic hyperpolarization than drugs that are more effective on GluN2A or 
B receptors (such as MK801) [38]. The counterexample is memantine, which has an 
affinity for GluN2C receptors similar to ketamine but does not cause clinical seda-
tion. Memantine and ketamine have a markedly different trapping blocks, which 
may explain this difference in results.
NMDAR knockout animals should be completely resistant to ketamine. Petrenko 
and colleagues discovered that knockout mice lacking the NMDA receptor GluE 
epsilon1 subchain are resistant to ketamine hypnosis. Furthermore, these animals 
cannot be sedated by anesthetics or pentobarbital, which do not directly block 
NMDA, implying that their excitatory effects are nonspecific. Based on their find-
ings, the authors concluded that the decreased ketamine sensitivity of animals was 
due to a compensatory increase in monoaminergic tone, which would help reduce 
hypnotic tendencies rather than a genetic knockout of NMDA receptors [39].
Furthermore, ketamine has been shown to hypnotize by interacting with other 
receptor types. Its hypnotic activity was reduced by 30% in a mouse model with condi-
tional forebrain knockout of the HCN1 channel [40, 41]. Rather, it promotes wakeful-
ness by increasing aminergic [42] and cholinergic activity in the neocortex [43].
5. Pain
In concentrations similar to that which produces psychotomimetic effects 
(200 ng/ml), ketamine reduces pain scores. In addition to producing hypnotic, 
analeptic, and anti-nociceptive effects, it also exhibits an unusual mix of anti- and 
pro-nociceptive properties. It is still largely debated whether ketamine is a useful 
analgesic in clinical practice or not. A careful examination of its analgesic effects is 
required, with the analgesic effects being compared to the specific pain syndrome 
[42] in question [44, 45]. Notably, norketamine has been reported to have anti-
analgesic effects [46], while ketamine can facilitate endogenous pain pathways 
under certain conditions. Because the drug’s analgesic effects are often accompanied 
by excessive sedation or psychotomimetic effects, its widespread use is somewhat 
limited. In many cases, the mechanism of direct receptor-mediated analgesia is 
dependent on drug levels for their analgesic effect. Long post-drug analgesia has 
been shown to outlast the effective drug levels in chronic neuropathic pain syn-
dromes, which indicates that downstream mechanisms are involved [46–48].
Ketamine also directly stimulates opioid mu-receptors, acting as an opioid 
mu-receptor agonist, and is considered to have the strongest anti-nociceptive effect 
[49]. It undoubtedly alters opioid receptor responsiveness [50]. A series of studies 
using G protein-coupled inwardly rectifying potassium channels (GIRK2s) knock-
out mice have provided evidence for the hypothesis that opioids and clonidine exert 
a significant portion of their analgesic effects via the influence of these channels. In 
contrast to opioids, ketamine’s analgesic effects have been associated with increased 
dopamine activity in mice [46]. Among the patients suffering from chronic pain, 
ketamine probably reduces opioid tolerance more than other opioid antagonists. 
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A recent study by Gupta and colleagues showed that ketamine has anti-desensi-
tization effects in vitro, acting by reducing ERK1/2 phosphorylation and reverses 
opioid receptor desensitization [51].
A potential mechanism through which ketamine augments endogenous anti-
nociceptive systems might be its stimulation of aminergic pathways (serotonin 
and noradrenergic) and inhibition of its reuptake [52]. The analgesic effects of 
Ketamine may also be related to its inhibition of nitric oxide synthase [53], although 
the relative importance of these mechanisms has not been determined to date.
5.1 Control of chronic pain
Ketamine can have long- and short-term effects on chronic neuropathic pain. 
Low-dose analgesics (250 mg/kg) can reduce ongoing pain, allodynia, and hyper-
algesia symptoms quickly (within 5 minutes) and transiently (within 2 to 3 hours) 
[54]. The latter could be explained by an NMDA-mediated “wind-up” reduction 
[55]. Nonetheless, these effects do not follow a consistent pattern from one person 
to the next. Even within the same subject group, there is the possibility of tempo-
rary (<2 hours), long-lasting (6–24 hours), and no analgesic effects [48]. Ketamine 
has even been shown to reduce chronic postsurgical pain for up to 180 days after a 
single infusion around the time of surgery [56].
In clinical studies, ketamine was found to be capable of producing long-lasting 
analgesic effects. According to the literature, some of these indicators may contradict 
clinical observations. In this case, ketamine’s antidepressant effect may explain why 
the drug has a preemptive effect on neuropathic pain that lasts long after the drug is no 
longer present [57, 58]. Although the cause of the causal link between depression and 
chronic pain is more often unknown, pain and depression are closely tied. Furthermore, 
its ability to inhibit gradual pathophysiological changes may help to prevent the devel-
opment of chronic pain by inducing signaling cascades [59]. According to the previous 
section, ketamine affects several gene expression pathways that may affect the etiology 
of chronic pain, including the expression of NMDA receptors and astrocytic activity. 
This drug’s effects would last much longer than its detectable presence.
6. Antidepressant effects of ketamine
Recent studies have shown that ketamine can be a powerful antidepressant that 
works quickly. This time-of-onset, however, lasts for about a week, and the antide-
pressant effect lasts about 2 hours. This is indicative of ketamine-induced signaling 
cascades that happen long after the substance has been eliminated [60]. By review-
ing all the putative mechanisms, Duman and colleagues suggest [4] that ketamine 
at low doses increases glutamate neurotransmission by both increasing glutamate 
release and increasing insertion of the AMPA receptors into synaptic vesicles. This 
leads to increased BDNF release and thus activation of ERK signaling, which then 
stimulates mammalian targets of rapamycin (mTOR). A protein translation kinase 
stimulates synaptic protein synthesis (GluR1) and increases synaptic density and 
insertion through a complex signal pathway. Furthermore, it increases structural 
connectivity between neurons, slowing down the aging process.
7. Conclusion
Ketamine affects a range of neuronal processes within cells, including the 
well-known NMDA receptor blockade. According to the results, blockage of NMDA 
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and HCN1 channels likely causes hypnotic effects to occur. On the other hand, the 
antidepressant-induced long-term effects are likely a result of its post-therapeutic 
effect. Ketamine’s analgesic effects appear to be mediated by both short- and long-
term changes in cellular function. Analgesic effects are probably mediated primarily 
through opioid system activation and the antinociceptive effects of the amine, 
whereas neuropathic pain is suppressed through receptor-mediated mechanisms 
and sustained cell signaling pathways.
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